View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 29, 2020

Second Covid-19 vaccine trial commences in Russia

Clinical trials of second Covid-19 vaccine candidate in Russia have commenced at the Vector virology institute in Siberia, according to RIA news agency.

Clinical trials of second Covid-19 vaccine candidate in Russia have commenced at the Vector virology institute in Siberia, according to RIA news agency.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The first five participants were dosed on 27 July. Citing consumer safety watchdog Rospotrebnadzor, RIA said that the next volunteer would be vaccinated on 30 July.

Reuters added that a government clinical trials register shows that the institute is assessing a peptide vaccine based on a platform initially developed for Ebola.

The trial of the Covid-19 vaccine candidate is expected to scale up to 100 participants aged 18 and 60 years.

Based on the World Health Organization (WHO) records, the Vector virology institute is working on six different potential Covid-19 vaccines.

The country’s first Covid-19 vaccine candidate had already entered initial trials. The candidate is an adenovirus-based vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology.

An early stage trial was completed this month and the vaccine is expected to advance into large-scale trials next month.

Russia granted authorisation for clinical trials of two formulations of Gamaleya’s  Covid-19 vaccine candidate.

An intramuscular solution of the vaccine was tested at the Burdenko Military Hospital while Sechenov University assessed the vaccine in the form a powder for the preparation of an intramuscular solution.

Data found that the candidate was safe and induced an immune response in participants.

The primary objective of the trial was to assess the safety and tolerability of the Covid-19 vaccine components in the first group of 18 subjects.

For 28 days following vaccination, the vital signs of the participants were within normal limits, without any report of serious adverse events, health complaints, complications, or adverse reactions.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena